Maintains Outperform
https://www.benzinga.com/stock/GBT/ratings
Wednesday, October 9, 2019
Viela Bio in deal with Mitsubishi Tanabe Pharma to develop inebilizumab in Asia
Viela Bio (NASDAQ:VIE) collaborates with Mitsubishi Tanabe Pharma (OTCPK:MTZPY)
to develop and commercialize inebilizumab – Viela’s humanized anti-CD19
monoclonal antibody in nine Asia regions for neuromyelitis optica
spectrum disorder, as well as other potential future indications.
Under the terms of collaboration, Viela will
receive an up-front licensing fee of $30M as well as additional
milestone payments and payments based, in part, on sales revenue.
MTPC will be responsible for development and
commercialization of inebilizumab in Japan, Thailand, South Korea,
Indonesia, Vietnam, Malaysia, Philippines, Singapore, and Taiwan.
https://seekingalpha.com/news/3504650-viela-bio-inks-deal-mitsubishi-tanabe-pharma-develop-inebilizumab-asiaIonis earns $10M milestone from Bayer on advancement of clotting disorder med
Ionis Pharmaceuticals (NASDAQ:IONS) announces that collaboration partner Bayer (OTCPK:BAYRY) has decided to advance antisense candidate IONIS-FXI-Lrx for the potential treatment of clotting disorders.
Under their May 2015 agreement, Bayer has
exclusive rights to develop Ionis’ Factor XI-targeting programs for
clotting disorders. Its decision to proceed with this candidate triggers
a $10M milestone payment to Ionis, who is eligible for additional
milestones and tiered royalties in the low-to-high 20% range on gross
margins.
https://seekingalpha.com/news/3504651-ionis-earns-10m-milestone-bayer-advancement-clotting-disorder-candidateAnavex launches Anavex 2-73 extension study in Alzheimer’s
Anavex Life Sciences (NASDAQ:AVXL) has initiated a long-term extension study, ATTENTION-AD, for patients with early Alzheimer’s disease treated with ANAVEX 2-73 (blarcamesine).
It will be conducted in parallel with the Phase 2b/3 ANAVEX2-73-AD-004 trial.
https://seekingalpha.com/news/3504656-anavex-launches-anavex-2minus-73-extension-study-alzheimer-sPremarket analyst actions, Oct. 9
Vericel (NASDAQ:VCEL) initiated with Buy rating and $19 (37% upside) price target at H.C. Wainwright.
QIAGEN (NYSE:QGEN) downgraded to Reduce at Kepler Cheuvreux.
https://seekingalpha.com/news/3504657-wainwright-likes-vericel-premarket-analyst-action
Cure Pharma launches chewable drug delivery system
Aimed at meeting demand for alternative dosage forms that improve solubility and absorption, CURE Pharmaceutical (OTCQB:CURR) announces CUREpods,
a chewable drug delivery system, as well as nano and microemulsions
that can be incorporated into a range of dosage forms, including
CUREfilm.
To meet the increased demand, the company is
expanding its manufacturing footprint by 50% via new blending, casting
and packaging equipment.
https://seekingalpha.com/news/3504664-cure-pharma-launches-chewable-drug-delivery-systemJohnson & Johnson to appeal $8B Risperdal judgment
Predictably, Johnson & Johnson (NYSE:JNJ) intends to appeal the $8B in punitive damages
awarded by a Philadelphia jury to a man who claimed that the company
failed to adequately warn about the risk of breast growth associated
with the antipsychotic med Risperdal (risperidone).
The company regards the award as “grossly
disproportionate” with the initial compensatory award of $680K and a
violation of due process, adding that U.S. Supreme Court precedent
dictates that punitive damages that are double-digit multiples of
compensatory awards should be set aside.
Shares are down 2% premarket on light volume.
https://seekingalpha.com/news/3504671-johnson-and-johnson-appeal-8b-risperdal-judgement
Subscribe to:
Comments (Atom)